Advanced in Hypertrichosis Lanuginosa Congenita

Bertille Bonniaud

Dijon, FR 
Advanced in Hypertrichosis Lanuginosa Congenita
Dijon, FR 
OverviewLocationsClinical Research

Overview

Bertille Bonniaud practices in Dijon, France. Ms. Bonniaud is rated as an Advanced expert by MediFind in the treatment of Hypertrichosis Lanuginosa Congenita. Her top areas of expertise are Hypertrichosis Lanuginosa Congenita, Ambras Syndrome, Woolly Hair Syndrome, and Hypomelanosis of Ito.

Her clinical research consists of co-authoring 23 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Hypertrichosis Lanuginosa Congenita.

Gender
Female

Locations

Dijon, France
Other Locations
Paris, France
Bourgogne, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children and Adults: a Cluster Multicenter Randomized Trial
Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children and Adults: a Cluster Multicenter Randomized Trial
Enrollment Status: Completed
Publish Date: June 17, 2024
Intervention Type: Drug
Study Drugs: Ivermectin, Permethrin
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
View 2 Less Clinical Trials

23 Total Publications

Survival study of cervico-facial melanomas at 3 years without recurrence: impact of non-analysis of the sentinel lymph node.
Survival study of cervico-facial melanomas at 3 years without recurrence: impact of non-analysis of the sentinel lymph node.
Journal: Journal of stomatology, oral and maxillofacial surgery
Published: June 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Bonniaud's expertise for a condition
ConditionClose
      View All 22 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile